January 5, 2018 / 12:24 PM / a year ago

REFILE-Kala Pharma posts mixed results from dry eye disease drug studies

(Corrects dateline to Jan 5)

Jan 5 (Reuters) - Kala Pharmaceuticals Inc on Friday reported mixed results from two late-stage trials testing its drug to provide temporary relief from the signs and symptoms of dry eye disease.

The drug, KPI-121, met the main goals of reducing redness and discomfort in the eye in one trial, but failed to show statistical significance on a scale that tested patients’ eyes using a corneal staining technique.

The second trial met the main goal of reducing a sign of dry eye, but failed another main goal of reducing discomfort in the eye, a symptom of the disorder.

Reporting by Manas Mishra and Tamara Mathias in Bengaluru; Editing by Martina D'Couto

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below